Chicago, IL (PRWEB) December 1, 2006
Resonate Capital Management, LLC has acquired 50,000 common shares of an early stage aids vaccine manufacturer GeoVax Labs, Inc of Atlanta.
The firm accumulated the common shares at open market pricing over the last seven trading days. Tony Wissel, A managing member of Resonate Capital believes that due to GeoVax’s recent merger with Dauphin Technology, the stock has become extremely undervalued and that even at this early stage GeoVax has the potentail for a significantly higher valuation. Resonate Capital specializes in acquiring shares of early stage companies that they believe are either unervalued in the market or have been the subject of recent mergers. Resonate Capital Manages the RCM fund one with offices in Chicago, Illinois and Kansas City, Missouri.
Any further inquiries please contact Resonate Capital, LLC at 312 953-9947.
# # #